MeONa–Et2Zn. (0.5) 1H NMR: δ Ϫ0.05 (q, CH2), 1.53
(t, CH3CH2) and 3.51 (s, CH3O).
(s and s, CH3Si), 1.58 and 1.78 (s and s, CH3CO) and 3.01
(s, 18C6). (1.5 : 1.5 : 1) δ Ϫ0.49 (s, CH2), 0.48 (s, CH3Si), 1.55
(s, CH3CO) and 2.98 (s, 18C6).
MeOK–Bu2Zn. (0.5) 1H NMR: δ 0.02 (t, CH2Zn), 1.13
(t, CH3CH2), 1.25 (m, CH2CH3), 1.87 (m, CH2CH2Zn) and 3.49
(s, CH3O).
Bu4NCl–Bu2Zn. (1) 1H NMR (lower phase): δ 0.6 (br,
CH2Zn), 3.2 (br, CH2N) and 1.0–2.2 (c, all other H).
Bu4NCl–(Me3SiCH2)2Zn. (0.5) 1H NMR (300 MHz): δ Ϫ0.50
(s, CH2Zn), 0.47 (s, CH3Si), 0.95 (t, CH3CH2), 1.38–1.42
(c, CH2CH2CH2N) and 2.88 (br m, CH2N). (1) δ Ϫ0.44
(s, CH2Zn), 0.48 (s, CH3Si), 0.93 (t, CH3CH2), 1.37–1.41
(c, CH2CH2CH2N) and 2.85 (br m, CH2N).
1
MeOK–s-Bu2Zn. (0.5) H NMR: δ 0.12 (m, CHZn), 1.17 (t,
CH3CH2), 1.36 (d, CH3CH), 1.79 (m, CH2) and 3.52 (s, CH3O).
t-BuOK–Et2Zn. A solution resulted when t-BuOK (1.80 g,
16 mmol) and Et2Zn (1.98 g, 16 mmol) were stirred in toluene
(8.0 mL), but white crystals soon formed. The sample was
heated to 80 ЊC to dissolve the solid. Crystals formed again
on slow cooling to ambient temperature. The sample was then
cooled at Ϫ5 ЊC for 24 h. The liquid was decanted and the
crystals were washed twice with benzene and allowed to dry
(mp 145–148 ЊC). A 6 mg sample of the crystals dissolved
Bu4NBr–Bu2Zn. (0.5) 1H NMR (300 MHz): δ 0.51 (t,
CH2Zn), 0.8–1.9 (c, overlapping absorptions of CH3CH2CH2-
CH2Zn and CH3CH2CH2CH2N) and 3.02 (br m, CH2N).
(1) δ 0.56 (t, CH2Zn), 0.9–1.9 (c, overlapping absorptions of
CH3CH2CH2CH2Zn and CH3CH2CH2CH2N) and 2.99 (br m,
CH2N).
1
completely in 0.5 mL of benzene-d6 (intensities of H NMR
absorptions indicated a 1 : 2 ratio of t-BuO and Et groups).
1H NMR: δ Ϫ0.16 (q, CH2), 1.18 (s, CH3CO) and 1.62 (t,
CH3CH2). 13C NMR: δ 7.0 (CZn), 14.2 (CH3), 33.8 (CCO) and
69.1 (CO).
PhN(Me)K–Et2Zn. (0.5) 1H NMR (300 MHz): δ Ϫ0.02
(q, CH2), 1.51 (t, CH3CH2), 2.66 (s, CH3N), 6.04–6.20 (c, o-H
and p-H) and 6.70 (t, m-H).
1
t-BuOK–Bu2Zn. (0.5) H NMR: δ Ϫ0.04 (t, CH2Zn), 1.09
PhN(Me)K–i-Bu2Zn. (0.5) 1H NMR (300 MHz): δ 0.12
(d, CH2Zn), 1.16 (d, CH3CH), 2.15 (m, CH), 2.63 (s, CH3N),
6.16–6.21 (c, o-H and p-H) and 6.95 (t, m-H).
(s, CH3CO), 1.25 (t, CH3CH2), 1.29 (m, CH2CH3) and 1.87
(m, CH2CH2Zn). 13C NMR: δ 14.4 (CH2Zn), 17.3 (CH3CH2),
30.5 (CH2CH3), 32.6 (CH2CH2Zn), 35.3 (CH3CO) and 68.4
(CO). (1) 1H NMR: δ Ϫ0.09 (t, CH2Zn), 1.12 (s, CH3CO), 1.20
(t, CH3CH2), 1.27 (m, CH2CH3) and 1.95 (m, CH2CH2Zn). 13
C
PhN(Me)K–(CH3CH2CHEtCH2)2Zn. (0.5) 1H NMR (300
MHz): δ Ϫ0.10 (d, CH2Zn), 1.15 (t, CH3CH2), 1.20–1.85
(c, CH(CH2CH3)2), 2.60 (s, CH3N), 6.15–6.23 (c, o-H and p-H)
and 6.94 (t, m-H).
NMR: δ 14.6 (CH2Zn), 17.4 (CH3CH2), 30.7 (CH2CH3), 32.8
(CH2CH2Zn), 35.5 (CH3CO) and 67.9 (CO). (0.75) (toluene-d8)
1H NMR: δ 0.00 (t, CH2Zn), 1.10 (s, CH3CO), 1.17 (t,
CH3CH2), 1.25 (m, CH2CH3) and 1.87 (m, CH2CH2Zn).
1H NMR (Ϫ80 ЊC): δ Ϫ0.27 (t, CH2Zn), 1.09 (s, CH3CO), 1.60
(t, CH3CH2), 1.40 and 1.52 (m and m, CH2CH3) and 2.24
(m, CH2CH2Zn).
PhN(Me)K–(Me3SiCH2)2Zn. (0.5) 1H NMR (300 MHz):
δ Ϫ1.01 (s, CH2), 0.32 (s, CH3Si), 2.68 (s, CH3N), 6.06–6.17
(c, o-H and p-H) and 6.89 (t, m-H).
t-BuOK–18C6–Bu2Zn. (0.4 : 0.4 : 1) 1H NMR: δ 0.55 (t, CH2-
Zn), 1.20 (t, CH3CH2), 1.60 (s, CH3CO), 1.75 (m, CH2CH3),
2.15 (m, CH2CH2Zn) and 3.04 (s, 18C6). 13C NMR: δ 17.1
(CH2Zn), 21.5 (CH3CH2), 27.4 (CH2CH3), 32.4 (CH2CH2Zn),
35.4 (CH3CO), 68.1 (CO) and 70.0 (18C6). (0.75 : 0.75 : 1)
1H NMR: δ 0.42 (t, CH2Zn), 1.19 (t, CH3CH2), 1.55 and 1.59
(s and s, CH3CO), 1.73 (m, CH2CH3), 2.09 and 2.20 (m and
m, CH2CH2Zn) and 3.06 (s, 18C6). 13C NMR: δ 17.2 and 17.3
(CH2Zn), 21.6 (CH3CH2), 27.7 and 28.2 (CH2CH3), 32.4 and
32.6 (CH2CH2Zn), 35.5 (CH3CO), 68.3 (CO) and 69.9 (18C6).
TolSK–Et2Zn. 1H NMR: δ Ϫ0.08 (q, CH2) and 1.62 (t, CH3).
TolSK–18C6–Et2Zn. 1H NMR (lower phase): δ 0.28 (q, CH2),
1.49 (t, CH3) and 3.00 (s, 18C6).
1
TolSK–i-Bu2Zn. H NMR: δ Ϫ0.06 (d, CH2), 1.18 (d, CH3)
and 2.20 (m, CH).
1
(1.5 : 1.5 : 1) H NMR: δ 0.40 (t, CH2Zn), 1.17 (t, CH3CH2),
TolSK–18C6–i-Bu2Zn. 1H NMR (lower phase): δ 0.46 (d,
CH2), 1.34 (d, CH3), 2.22 (m, CH) and 2.99 (s, 18C6).
1.49 (br, CH3CO), 1.71 (m, CH2CH3), 2.09 (m, CH2CH2Zn)
and 3.03 (s, 18C6). 13C NMR: δ 17.3 (CH2Zn), 21.6 (CH3CH2),
28.2 (CH2CH3), 32.7 (CH2CH2Zn), 35.1 (CH3CO), 68.1 (CO)
and 70.0 (18C6).
TolSK–(Me3SiCH2)2Zn. 1H NMR: δ Ϫ1.13 (s, CH2) and 0.24
(s, CH3).
1
t-BuOK–s-Bu2Zn. (0.5) H NMR: δ 0.18 (m, CHZn), 1.02
(t, CH3CH2), 1.08 (s, CH3CO), 1.32 (d, CH3CH) and 1.68 (m,
CH2). (1) H NMR: δ 0.03 (m, CHZn), 1.07 (s, CH3CO), 1.18
(t, CH3CH2), 1.40 (d, CH3CH) and 1.86 (m, CH2).
TolSK–18C6–(Me3SiCH2)2Zn. 1H NMR (lower phase):
δ Ϫ0.50 (s, CH2), 0.43 (s, CH3) and 2.98 (s, 18C6).
1
TolSK–(Tol)2Zn. 1H NMR: δ 2.15 (s, CH3), 7.05 (d, m-H) and
7.99 (d, o-H).
1
t-BuOK–(Me3SiCH2)2Zn. (1) H NMR: δ Ϫ1.13 (s, CH2),
0.32 (s, CH3Si) and 1.09 (s, CH3CO). (0.5) 1H NMR: δ Ϫ1.01 (s,
CH2), 0.28 (s, CH3Si) and 1.08 (s, CH3CO). (0.74) (toluene-d8)
1H NMR: δ Ϫ1.01 (s, CH2), 0.35 (s, CH3Si) and 1.09 (s,
CH3CO). (Ϫ80 ЊC) δ Ϫ1.12 and Ϫ1.30 (s and s, CH2), 0.38 and
0.42 (s and s, CH3Si), 1.18 and 1.20 (s and s, CH3CO).
Ph2PK–Et2Zn. 1H NMR: δ Ϫ0.09 (q, CH2) and 1.59 (t, CH3).
Ph2PK–18C6–Et2Zn. 1H NMR (lower phase): δ 0.30 (d,
CH2), 1.51 (t, CH3) and 2.99 (s, 18C6).
t-BuOK–18C6–(Me3SiCH2)2Zn.(0.4 : 0.4 : 1)1HNMR(lower
phase): δ Ϫ0.50 and Ϫ0.58 (s and s, CH2), 0.44 and 0.47 (s and
s, CH3Si), 1.58 and 1.76 (s and s, CH3CO) and 2.98 (s, 18C6).
(0.8 : 0.8 : 1) δ Ϫ0.41 and Ϫ0.46 (s and s, CH2), 0.46 and 0.49
1
Ph2PK–i-Bu2Zn. H NMR: δ Ϫ0.04 (d, CH2), 1.18 (d, CH3)
and 2.20 (m, CH).
J. Chem. Soc., Dalton Trans., 2001, 783–788
787